All News

2021

April

Media Release / Apr 23, 2021

Novartis to initiate SMART Phase 3b global study of Zolgensma in children up to 21 kg, building on real-world experience

Read More

March

Media Release / Mar 15, 2021

New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment

Read More
2020

December

Media Release / Dec 14, 2020

Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19

Read More

November

Media Release / Nov 06, 2020

Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)

Read More

October

Media Release / Oct 01, 2020

Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievement

Read More

September

Key Release / Sep 23, 2020

Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program

Read More

July

Media Release / Jul 16, 2020

Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19

Read More

June

Media Release / Jun 01, 2020

AveXis Community Statement on the Global Managed Access Program for AVXS-101

Read More

May

Media Release / May 19, 2020

AveXis receives EC approval and activates “Day One” access program for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)

Read More

April

Key Release / Apr 28, 2020

Novartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19

Read More

Key Releases

Ad hoc announcement pursuant to article 53 Listing Rules.

Learn More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

Learn More